Allogene Therapeutics, Inc. (ALLO) Financials

ALLO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 396.0 million 117.1 million
Dec. 31, 2025 415.9 million 123.4 million
Sept. 30, 2025 439.8 million 124.4 million
June 30, 2025 470.6 million 126.0 million

ALLO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -12.9 million 8.3 million
Dec. 31, 2025 -27.6 million 8.1 million
Sept. 30, 2025 -29.9 million 8.7 million
June 30, 2025 -39.1 million 8.7 million

ALLO Net Income

No data available :(

ALLO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 266.9 million - 72.6 million
Dec. 31, 2025 250.2 million - 83.3 million
Sept. 30, 2025 252.2 million - 77.1 million
June 30, 2025 273.1 million - 79.2 million

ALLO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 240.3 million
Dec. 31, 2025 220.6 million
Sept. 30, 2025 222.0 million
June 30, 2025 218.9 million

ALLO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 9000 29.1 million 14.1 million -
Dec. 31, 2025 - 28.6 million 13.8 million -
Sept. 30, 2025 243000 31.2 million 13.7 million -
June 30, 2025 44000 40.2 million 14.3 million -

ALLO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 2.9 million
Dec. 31, 2025 - 3.1 million
Sept. 30, 2025 - 31.2 million
June 30, 2025 - 3.1 million

ALLO Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ALLO

Price: $1.92

52 week price:
0.98
4.46

Earnings Per Share: -0.77 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 358933

Market Capitalization: 458.5 million

Links: